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Conclusion: Hypofractionated dose escalated radiation
treatment using IG-IMRT with Tomotherapy seems to be
feasible and well tolerated being able to obtain optimal
outcomes reducing total treatment time without increasing
acute and severe side-effects. Hypofractionation and dose
escalation in radical or concomitant (hormonotherapy) setting
should be considered in the management of non surgical
prostate cancer.
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Introduction: The modified Clavien classification system
(CCS) has been proposed to classify and grade complications
in general surgery. It is increasingly becoming popular in
urology although has never been used to date in common
procedures such as transurethral resection of bladder tumor
(TURB). The aim of our study is to evaluate the applicability
of the modified CCS in reporting and grading the severity of
perioperative complications in patients with bladder tumor
treated with TURB. Patients and Methods: A consecutive
series of patients with bladder lesions who underwent
transurethral resection of bladder tumour (TURB) from April
2011 to August 2011 at six academic centres were evaluated
for complications occurring up to the end of the first
postoperative month. Variables analyzed for each patient were:
age, sex, diabetes, hypertension, ischemic heart disease, score,
tumor size, number of lesions, grade of tumor, anticoagulation
therapy, type of diversion, operation time, preoperative
hydronefrosis and BMI. All complications were prospectively
recorded and classified according to the modified CCS.
Results were presented as complication rates per grade. Chi-
square, Kruskal Wallis tests and logistic regression analysis
were used for statistical analysis. Results: 275 patients were
consecutively enrolled. Mean age was 68.26±8.1 years; mean
BMI was 28.3±4 Kg/m2, mean tumour size was 2.38±2.3 cm;
mean number of tumour lesions was 2.52±2.3. All patients
underwent a monopolar TURB. Mean operative time was
43±28 m. Fifty-six complications were recorded in 51 patients.
Overall perioperative morbidity rate was 18.5%. Most of them
were not serious (haematuria and clot retention) and were
classified as Clavien type I (42 cases; 75%) or II (8 cases,
14%). Higher grade complications were scarce: CCS IIIb in
six cases (11%). No TURB related death was reported. Six
patients were re-operated due to significant bleeding or clot
retention on postoperative days 2-7. No significant association
between Age, sex, ASA score, anti-coagulant treatment, BMI,
tumor size, number of lesions, diabetes, hypertension,
ischemic heart disease and hospital stay with the number of
complications were observed. On univariate (73.5±38 vs.
36.7±21.6 minutes) and multivariate analysis longer operative
time was the only independent parameter associated with a
higher risk of CCS type I complications (OR: 1.040 per
minute, 95%CI 1.025-1.055, p=0.001). Grade Complications I
42 II 8 IIIb 6 IV 0 V 0. Conclusion: The modified CCS
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represents a practical and easily applicable tool that may help
urologists to classify the complications of TURB in a more
objective and detailed way. In our experience, using this CCS
tool, TURB is a safe procedure with a low morbidity rate.
Post-operative bleeding is the most significant complication
that determines a reoperation. A longer operative time is a
significant risk factor for not serious post-operative
complications. 
1 Dindo D, Demartines N and Clavien PA: Classification of
surical complications: a new proposal with evaluation in a
cohort of 6336 patiens and result of a survey. Ann Surg 240:
205-213, 2004.
2 Mamoulakis C, Efthimiou I, Kazoulis S et al: The modified
Clavien classification system platform for reporting
complications in transurethral resection of prostate. World J
Urol 29: 205-221, 2011.
108
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Objective: HIFU is a minimally invasive treatment based on
thermal ablation of tissues which are warmed up to 85˚C in
the focal area. Clinical studies have shown such treatment
modalit y to be safe and effective in the management of
localised prostate cancer (1) as well as of local recurrences
after radical prostatectom y or radiotherapy (2), but there are
still few data in patients with high -risk localised prostate
cancer: clinical stage > o or =T2c or Gleason score 8-10 or
PSA >20 (3). Patients and Methods: From May 2 002 to
February 2012, 179 patients with no previous treatment for
prostate cancer, aged 44 to 86 years (mean 75) underwent 206
HIFU treatments; 27 patients needed a second treatment as the
first was incomplete (4 patients) or because of recurrence (23
patients). The prognosis subgroups were defined as low -risk
in 29 patients (clinical stage T1-T2a, PSA < or = 10 ng/mL
and Gleason score lower than 7), intermediate -risk in 47
patients (clinical stage T2b or PSA 10-20 ng/mL or Gleason
score of 7), and high-risk in 103 patients (clinical stage > or =
T2c or PSA >20 ng/mL or Gleason score higher than 7).
Results: At a mean follow -up of 79.3 months, biochemical
success rate (PSA constantl y <0.5 ng/ml) was obtained in
82.8% of low and intermediate risk patients and in 42.7% of
high risk patients; post -treatment biopsies (6 months after
treatment) revealed no residual tumour in 92.1% of low or
intermediate risk patients and in 58.2% of high risk patients.
Conclusion: Radical prostatectomy remains the “gold
standard” for localised prostate cancer. However, HIFU seems
to be a promising alternative and less invasive treatment
modality with an encouraging success rate, at least in the
short-term, in patients with low and medium risk of
progression, not candidates for radical surgery; in cancers with
clinical stage >or=T2c, or PSA >20 ng/m L, or Gleason score
higher than 7 seems to get good results in about half of
patients. 
1 Thüroff S, Chaussy C, Vallancien G et al: High-intensity
focused ultrasound and localized prostate cancer: efficacy
results from the European multicentric study. J Endourol
17(8): 673, 2003. 
2 Berge V, Baco E and Karlsen SJ: A prospective study of
salvage high-intensity focused ultrasound for locally
radiorecurrent prostate can cer: early results. Scand J Urol
Nephrol 44(4): 223, 2010. 
3 Ficarra V, Zecchini S, Novara G et al: Short-term outcome
after high intensity focused ultrasound in the treatment of
patients with high-risk prostate cancer. BJU Int 98: 1193,
2006.
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Purpose: Nephroureterectomy with excision of a cuff of
bladder remains the standard for managing upper tract
transitional cell carcinoma, which could, in selected cases, be
managed conservatively (1). Patients and Methods: In 12 years
we have treated 169 reno-ureteral unities (r.u.u.) for urothelial
tumors; 107 r.u.u. with low-stage and low-grade disease (96
patients, 11 with bilateral tumor and 4 solitary kidney), were
treated by an endoscopic approach; in 62 cases (5 for high
grade recurrences after conservative approach)
nephroureterectomy was performed. In 107 r.u.u. treated by
ureteroscopic approach, we observed 5 high-grade recurrences
(nephroureterectomy) and 34 low-grade (G1-G2) recurrences.
Each r.u.u. received an average of 2.5 ureteroscopic operative
procedures. The patients were followed up for a mean of 49.9
months after initial treatment and currently they are all
recurrence free. 11/96 patients with suspect tumor of the upper
tract (11.4%) had no carcinoma in the ureteroscopic biopsy.
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